Renal Insufficiency, Chronic Clinical Trial
Official title:
Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Effect of Ferric Citrate on Time to a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality vs Placebo in Adults With Advanced CKD
A 9-month randomized, double-blind, placebo-controlled study to compare the effect of fixed dose ferric citrate versus placebo in patients with advanced chronic kidney disease (eGFR ≤20 ml/min/1.73m2) on the composite endpoint of time to initiation of maintenance dialysis or all-cause mortality.
This multicenter, randomized, double-blind, placebo-controlled clinical trial is being conducted to determine the effect of ferric citrate on the time to a composite endpoint of initiation of maintenance dialysis or all-cause mortality in patients with non-dialysis dependent, advanced CKD. Up to 400 subjects will be randomized in 1:1 ratio to receive either ferric citrate or matching placebo. All subjects will initiate dosing at 2 tablets per meal or snacks, up to 3 times per day (maximum of 6 tablets per day). The dose of ferric citrate/placebo will only be adjusted based on safety and/or tolerability. Given the double-blind design of this trial, investigators will be instructed to not prescribe commercial Auryxia to either study arm. Study visits during the treatment period are to be conducted as part of routine scheduled clinical encounters. Standard of care local laboratory results will be collected however no study specific laboratory tests other than a pregnancy test in women of child-bearing potential will be required. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
| Withdrawn |
NCT01655186 -
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
|
Phase 2 | |
| Completed |
NCT03481686 -
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
|
N/A | |
| Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
| Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
| Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
| Terminated |
NCT01533545 -
Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
|
N/A | |
| Completed |
NCT03280615 -
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
|
Phase 3 | |
| Completed |
NCT04498156 -
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
|
||
| Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
| Recruiting |
NCT06366529 -
Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
|
||
| Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
| Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
| Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
| Completed |
NCT03577249 -
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
|
Phase 2/Phase 3 | |
| Completed |
NCT01975818 -
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
|
Phase 2 | |
| Active, not recruiting |
NCT05766644 -
App-based Education Program for CKD
|
N/A | |
| Active, not recruiting |
NCT02791880 -
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
|
||
| Recruiting |
NCT02947750 -
Neurovascular Transduction During Exercise in Chronic Kidney Disease
|
Phase 2 | |
| Terminated |
NCT02286258 -
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
|
Phase 1/Phase 2 |